Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

L MICHAEL WEISS

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1215026158
CMS profile
145469
Location
CLEARWATER, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$1,274.18

71 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,259.36 70
Education $14.82 1

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

L MICHAEL WEISS

NPI 1215026158 · CMS profile ID 145469

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

CLEARWATER, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1215026158?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
L MICHAEL WEISS, NPI 1215026158, CMS profile ID 145469. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1215026158?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). L MICHAEL WEISS, NPI 1215026158, CMS profile ID 145469. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1215026158?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
L MICHAEL WEISS, NPI 1215026158, CMS profile ID 145469, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1215026158?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

71 matching records · $1,274.18 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 71 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–71 of 71.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Salix Pharmaceuticals, a division of Bausch Health US, LLC $0.9105/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057063611 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $5.3505/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057225771 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $6.8705/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057375489 CMS
AbbVie Inc. $17.5805/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999579239 CMS
AbbVie Inc. $29.3705/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999579233 CMS
PFIZER INC. $23.2305/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050556743 CMS
Janssen Biotech, Inc. $23.4405/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988078254 CMS
Ironwood Pharmaceuticals, Inc $25.8705/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045573335 CMS
Celgene Corporation $20.6904/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015559593 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $5.8504/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057334887 CMS
AbbVie Inc. $17.0804/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999579227 CMS
Fresenius Kabi USA, LLC $24.0004/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060094083 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $24.6204/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057450081 CMS
AbbVie Inc. $22.3304/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999579221 CMS
AbbVie Inc. $18.9203/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999579217 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.6703/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055664293 CMS
Celgene Corporation $15.5203/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015559585 CMS
AbbVie Inc. $9.5303/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999579211 CMS
Ferring Pharmaceuticals Inc. $14.2002/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044255453 CMS
Ironwood Pharmaceuticals, Inc $18.7702/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045538377 CMS
Janssen Biotech, Inc. $24.2901/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988078241 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,093.59 15
PY2020 $267.34 7
PY2021 $62.06 3
PY2022 $464.17 25
PY2023 $1,274.18 71
PY2024 $754.34 30
PY2025 $1,501.92 55

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $285,899.86 90
PY2024 Principal investigator $338,643.08 85
PY2023 Recipient $859.89 1
PY2023 Principal investigator $240,205.84 74
PY2022 Principal investigator $82,420.84 46
PY2021 Principal investigator $122,620.13 34
PY2020 Principal investigator $270,128.12 134
PY2019 Recipient $8,000.00 1
PY2019 Principal investigator $322,477.22 92

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

90 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $157.00 12/19/2025 Non-covered Recipient Entity
W Ctrl Gastroenterology Llp
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175188472
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,490.64 12/19/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223289946
Principal investigator 1 Janssen Research & Development, LLC $157.00 12/17/2025 Non-covered Recipient Entity
W Ctrl Gastroenterology Llp
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175188186
Principal investigator 1 Janssen Research & Development, LLC $959.00 12/17/2025 Non-covered Recipient Entity
W Ctrl Gastroenterology Llp
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175188534
Principal investigator 1 Janssen Research & Development, LLC $348.00 12/12/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1175345611
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,500.00 12/10/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) No dispute reported 06/30/2026 1223289438
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $38.00 12/10/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) No dispute reported 06/30/2026 1223289440
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,550.00 12/10/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) No dispute reported 06/30/2026 1223289448
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,550.00 12/10/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) No dispute reported 06/30/2026 1223289450
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $38.00 12/10/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) No dispute reported 06/30/2026 1223289454
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,550.00 12/10/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) No dispute reported 06/30/2026 1223289462
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,500.00 12/10/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) No dispute reported 06/30/2026 1223289474
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $38.00 12/10/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) No dispute reported 06/30/2026 1223289476
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,747.00 12/10/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) No dispute reported 06/30/2026 1223289478
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,686.00 12/10/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) No dispute reported 06/30/2026 1223289480
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $919.00 12/10/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) No dispute reported 06/30/2026 1223289482
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $919.00 12/10/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) No dispute reported 06/30/2026 1223289484
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,125.00 12/10/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) No dispute reported 06/30/2026 1223289486
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,500.00 12/05/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY
ENTYVIO (VEDOLIZUMAB) LONG-TERM SAFETY STUDY: AN INTERNATIONAL OBSERVATIONAL PROSPECTIVE COHORT STUDY COMPARING VEDOLIZUMAB TO OTHER BIOLOGIC AGENTS IN PATIENTS WITH ULCERATIVE COLITIS OR CROHN'S DISEASE No dispute reported 06/30/2026 1223289338
Principal investigator 1 F. Hoffmann-La Roche AG $1,701.00 12/04/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211684824
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,426.92 12/04/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223289212
Principal investigator 1 Genentech, Inc. $6,256.00 11/25/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211684836
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,738.80 11/25/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223288707
Principal investigator 1 Genentech, Inc. $2,390.00 11/14/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211684834
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,426.92 11/14/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223288295
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,550.00 11/12/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) No dispute reported 06/30/2026 1223288185
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,550.00 11/12/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) No dispute reported 06/30/2026 1223288187
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,686.00 11/12/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) No dispute reported 06/30/2026 1223288189
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,125.00 11/12/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) No dispute reported 06/30/2026 1223288191
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $183.00 11/12/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) No dispute reported 06/30/2026 1223288193
Principal investigator 1 Genentech, Inc. $1,618.00 11/07/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211684838
Principal investigator 1 Genentech, Inc. $1,926.00 10/29/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211684830
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,025.84 10/29/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223287719
Principal investigator 1 Janssen Research & Development, LLC $1,975.00 10/23/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1175345618
Principal investigator 1 Genentech, Inc. $10,113.00 10/16/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211684832
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,426.92 10/16/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223287033
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $183.00 10/08/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) No dispute reported 06/30/2026 1223286475
Principal investigator 1 Bausch Health US, LLC $1,279.00 10/06/2025 Non-covered Recipient Entity
West Central Gastroenterology, LLP
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224848387
Principal investigator 1 Celgene Corporation $2,700.00 10/06/2025 Non-covered Recipient Entity
Gastro Health Central Broward
A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis. No dispute reported 06/30/2026 1222304599
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,549.22 10/03/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223286269
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,550.00 10/02/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) No dispute reported 06/30/2026 1223286209
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,550.00 10/02/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) No dispute reported 06/30/2026 1223286211
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,550.00 10/02/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) No dispute reported 06/30/2026 1223286213
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,500.00 10/02/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) No dispute reported 06/30/2026 1223286215
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,125.00 10/02/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) No dispute reported 06/30/2026 1223286217
Principal investigator 1 Janssen Research & Development, LLC $1,398.00 09/29/2025 Non-covered Recipient Entity
W Ctrl Gastroenterology Llp
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175188378
Principal investigator 1 Janssen Research & Development, LLC $174.00 09/22/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1175345585
Principal investigator 1 F. Hoffmann-La Roche AG $4,213.00 09/18/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211684820
Principal investigator 1 Celgene Corporation $6,800.00 09/10/2025 Non-covered Recipient Entity
Gastro Health Central Broward
A Multi-Center, Multi-National, Randomized, Double-Blind, Placebo-Controlled Induction and Long-term Controlled Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis. No dispute reported 06/30/2026 1222304585
Principal investigator 1 Bausch Health US, LLC $2,069.00 09/03/2025 Non-covered Recipient Entity
West Central Gastroenterology, LLP
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224848349
Principal investigator 1 Bausch Health US, LLC $1,198.00 09/03/2025 Non-covered Recipient Entity
West Central Gastroenterology, LLP
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224848352
Principal investigator 1 Janssen Research & Development, LLC $157.00 08/28/2025 Non-covered Recipient Entity
W Ctrl Gastroenterology Llp
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175188174
Principal investigator 1 F. Hoffmann-La Roche AG $1,341.00 08/26/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211684822
Principal investigator 1 Janssen Research & Development, LLC $174.00 08/20/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1175345595
Principal investigator 1 F. Hoffmann-La Roche AG $3,343.00 08/07/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211684818
Principal investigator 1 Janssen Research & Development, LLC $2,149.00 07/24/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1175345566
Principal investigator 1 Bausch Health US, LLC $1,593.00 07/23/2025 Non-covered Recipient Entity
West Central Gastroenterology, LLP
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224848345
Principal investigator 1 F. Hoffmann-La Roche AG $6,650.00 07/22/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211684816
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,494.16 07/22/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223282896
Principal investigator 1 Eli Lilly and Company $1,000.00 07/09/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
MIRIKIZUMAB LY3074828 PRO UC CD - OMVOH - ULCERATIVE COLITIS No dispute reported 06/30/2026 1187893326
Principal investigator 1 Bausch Health US, LLC $371.00 07/07/2025 Non-covered Recipient Entity
West Central Gastroenterology, LLP
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224848357
Principal investigator 1 Genentech, Inc. $1,812.00 06/19/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211684826
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,577.34 06/12/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223281176
Principal investigator 1 Bausch Health US, LLC $1,492.00 06/02/2025 Non-covered Recipient Entity
West Central Gastroenterology, LLP
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224848361
Principal investigator 1 Bausch Health US, LLC $371.00 06/02/2025 Non-covered Recipient Entity
West Central Gastroenterology, LLP
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224848367
Principal investigator 1 Bausch Health US, LLC $1,198.00 06/02/2025 Non-covered Recipient Entity
West Central Gastroenterology, LLP
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224848372
Principal investigator 1 Genentech, Inc. $8,302.00 05/27/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211684828
Principal investigator 1 Janssen Research & Development, LLC $348.00 05/23/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1175345627
Principal investigator 1 Janssen Research & Development, LLC $174.00 04/17/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1175345558
Principal investigator 1 Bausch Health US, LLC $1,548.00 04/02/2025 Non-covered Recipient Entity
West Central Gastroenterology, LLP
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224848363
Principal investigator 1 Bausch Health US, LLC $371.00 04/02/2025 Non-covered Recipient Entity
West Central Gastroenterology, LLP
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224848377
Principal investigator 1 Bausch Health US, LLC $137.00 04/02/2025 Non-covered Recipient Entity
West Central Gastroenterology, LLP
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224848382
Principal investigator 1 Janssen Research & Development, LLC $4,304.00 03/27/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1175345634
Principal investigator 1 Janssen Research & Development, LLC $157.00 03/20/2025 Non-covered Recipient Entity
W Ctrl Gastroenterology Llp
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175188442
Principal investigator 1 Janssen Research & Development, LLC $279.00 03/20/2025 Non-covered Recipient Entity
W Ctrl Gastroenterology Llp
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175188517
Principal investigator 1 Janssen Research & Development, LLC $2,418.00 03/20/2025 Non-covered Recipient Entity
W Ctrl Gastroenterology Llp
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) No dispute reported 06/30/2026 1175188614
Principal investigator 1 PFIZER INC. $5,052.90 03/19/2025 Non-covered Recipient Entity
West Central Gastroenterology LLP
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 52WEEK STUDY TO ASSESS THE EFFICACY AND SAFETY OF ETRASIMOD IN SUBJECTS WITH MODERATELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228775144
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,683.22 02/25/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223275527
Principal investigator 1 Janssen Research & Development, LLC $2,538.00 02/21/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1175345603
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,303.96 02/18/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223275353
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,762.00 02/11/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223275037
Principal investigator 1 Bausch Health US, LLC $1,492.00 02/07/2025 Non-covered Recipient Entity
West Central Gastroenterology, LLP
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224848341
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $61,858.00 02/06/2025 Non-covered Recipient Entity
Gastro Florida
An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice No dispute reported 06/30/2026 1235997227
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,308.48 02/05/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223274763
Principal investigator 1 PFIZER INC. $1,515.00 02/03/2025 Non-covered Recipient Entity
West Central Gastroenterology LLP
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228775243
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,159.06 01/21/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223274241
Principal investigator 1 Janssen Research & Development, LLC $174.00 01/20/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Phase 3, Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1175345578
Principal investigator 1 Bausch Health US, LLC $1,198.00 01/08/2025 Non-covered Recipient Entity
West Central Gastroenterology, LLP
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224848333
Principal investigator 1 Bausch Health US, LLC $371.00 01/08/2025 Non-covered Recipient Entity
West Central Gastroenterology, LLP
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224848336
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,995.48 01/07/2025 Non-covered Recipient Entity
WEST CENTRAL GASTROENTEROLOGY LLP
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223273621